ClinicalTrials.gg
RecruitingNCT04625257Updated Feb 23, 2024

COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)

An observational study in Coronavirus Infectious Disease 2019 (COVID-19), sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by University Hospital, Basel, Switzerland · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in COVID-19 by University Hospital, Basel, Switzerland — 1 open to participants now, 1 under way, none of them phase 3. COVID-19 · University Hospital, Basel, Switzerland.

Started
2020
with 9 others
Observational
9 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in COVID-19 by University Hospital, Basel, Switzerland, this one is one of 10 that started in 2020, is one of 9 observational ones, and was the 9th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 13 studies in COVID-19 by University Hospital, Basel, Switzerland is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in COVID-19 by University Hospital, Basel, Switzerland, or all of them as a file.
02

Study summary

This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland. To achieve this, crude ribonucleotide acid (RNA) extraction from saliva is validated in combination with next-generation sequencing (NGS) diagnostics and loop mediated amplification (LAMP) assays as well as point of care test (POCT) for rapid detection of viral antigens on patients' samples.

03

Conditions studied

  • Coronavirus Infectious Disease 2019 (COVID-19)

Browse trials for

Keywords

  • severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay
  • point of care tests (POCT)
  • next-generation sequencing (NGS) method
  • contact tracing
  • transmission chains
  • crude RNA extraction from saliva
  • loop mediated amplification (LAMP) assay
  • viral nucleic acid analysis platform
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Symptomatic patients arriving at the COVID-19 test center Feldreben in Muttenz, Basel Land and at Swiss TPH in Basel, Basel Stadt to get tested for COVID-19.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • symptomatic patients getting tested for COVID-19

Exclusion criteria

Exclusion Criteria:

  • mentally incompetent adults
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherSaliva based assay: crude RNA extraction

    Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.

  • OtherValidation of the NGS method

    Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.

  • OtherValidation of the LAMP assays

    The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.

  • OtherValidation of the POCT Antigen and Antibody tests

    Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.

06

What researchers measure

Primary outcomes

  1. qualitative method validation of the crude extraction in combination with the LAMP or the NGS (count values for detection)

    For all qualitative method validation, the qualitative and quantitative result of the Foederatio Analyticorum Medicinalium Helveticorum (FAMH) performed RT-PCR (patient does / does not have SARS-Cov-2 and if yes, how many "ct" values for detection) is considered as the gold standard against which the crude extraction in combination with the LAMP or the NGS method using univariate measures is compared.

    Time frame: single point assessment at baseline

07

Study locations

1 of 1 sites recruiting
  • Cantonal Office of Public Health, Economics and Health Directorate, Canton Basel-Landschaft
    Liestal, 4410, Switzerland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Dec 2024, 50 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 50 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2020
First posted
Nov 12, 2020
StartActual
Oct 24, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04625257
Collaborators
ETH Zurich Department for Biosystems, Science and Engineering, Kanton Basel- Landschaft
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Oct 24, 2020
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Feb 23, 2024

Study contacts

Miodrag Savic, Dr. med. Dr. med. dent.
Contact
miodrag.savic@usb.ch
+41 79 485 31 13
Juerg Sommer, Dr.
Contact
Miodrag Savic, Dr. med. Dr. med. dent.
principal investigator · Cantonal Office of Public Health, Economics and Health Directorate, Canton Basel-Landschaft

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion